|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:acquiredBy
|
gptkb:Corixa_(2005)
gptkb:Human_Genome_Sciences_(2012)
gptkb:ID_Biomedical_(2005)
gptkb:Reliant_Pharmaceuticals_(2007)
gptkb:Stiefel_Laboratories_(2009)
gptkb:Tesaro_(2019)
|
|
gptkbp:annualReport
|
https://www.gsk.com/en-gb/investors/annual-report/
|
|
gptkbp:CEO
|
gptkb:Emma_Walmsley
|
|
gptkbp:competitor
|
gptkb:Bayer
gptkb:Pfizer
gptkb:AstraZeneca
gptkb:Johnson_&_Johnson
gptkb:Merck_&_Co.
gptkb:Sanofi
gptkb:AbbVie
gptkb:Novartis
gptkb:Roche
gptkb:Bristol_Myers_Squibb
|
|
gptkbp:country
|
gptkb:United_Kingdom
|
|
gptkbp:divested
|
Haleon (2022)
consumer healthcare (Haleon, 2022)
|
|
gptkbp:dividendPaying
|
paid quarterly
|
|
gptkbp:ESRB_rating
|
AA (MSCI, 2023)
|
|
gptkbp:foundedBy
|
merger of Glaxo Wellcome and SmithKline Beecham
|
|
gptkbp:foundedYear
|
2000
|
|
gptkbp:fullName
|
gptkb:GlaxoSmithKline_plc
|
|
gptkbp:headquartersLocation
|
gptkb:London,_United_Kingdom
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
GSK
|
|
gptkbp:industry
|
gptkb:biotechnology
pharmaceuticals
|
|
gptkbp:keyPerson
|
gptkb:Emma_Walmsley
gptkb:Hal_Barron
gptkb:Iain_Mackay
gptkb:Jonathan_Symonds
|
|
gptkbp:legalForm
|
gptkb:public_company
|
|
gptkbp:listedOn
|
gptkb:London_Stock_Exchange
gptkb:New_York_Stock_Exchange
|
|
gptkbp:logo
|
GSK logo.svg
|
|
gptkbp:marketCap
|
£60+ billion (2023)
|
|
gptkbp:memberOf
|
gptkb:FTSE_100_Index
gptkb:Pharmaceutical_Research_and_Manufacturers_of_America
|
|
gptkbp:netIncome
|
£4.6 billion (2023)
|
|
gptkbp:notableEvent
|
COVID-19 vaccine development
Haleon spin-off (2022)
merger of Glaxo Wellcome and SmithKline Beecham (2000)
|
|
gptkbp:notableProduct
|
gptkb:Advair
gptkb:Augmentin
gptkb:Avodart
gptkb:Bexsero
gptkb:Flovent
gptkb:Horlicks
gptkb:Lamictal
gptkb:Pandemrix
gptkb:Rotarix
gptkb:Seretide
gptkb:Shingrix
gptkb:Synflorix
gptkb:Ventolin
gptkb:Zovirax
|
|
gptkbp:numberOfEmployees
|
~69,000
~69,000 (2023)
|
|
gptkbp:parentCompany
|
none
|
|
gptkbp:predecessor
|
gptkb:Glaxo_Wellcome
gptkb:SmithKline_Beecham
|
|
gptkbp:products
|
vaccines
prescription medicines
consumer healthcare products
|
|
gptkbp:researchInterest
|
gptkb:HIV
immunology
infectious diseases
oncology
respiratory diseases
|
|
gptkbp:revenue
|
£29.3 billion (2023)
|
|
gptkbp:servesArea
|
worldwide
|
|
gptkbp:stockExchange
|
gptkb:London_Stock_Exchange
gptkb:New_York_Stock_Exchange
|
|
gptkbp:stockSymbol
|
gptkb:GSK
|
|
gptkbp:subsidiary
|
gptkb:Stiefel_Laboratories
gptkb:ViiV_Healthcare
|
|
gptkbp:website
|
https://www.gsk.com/
|
|
gptkbp:bfsParent
|
gptkb:Erica_Mann
gptkb:Mammoth_Biosciences
gptkb:Grey_New_York
gptkb:PCV10
|
|
gptkbp:bfsLayer
|
5
|